Meeting
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC).
Authors
Fergus Keane
Memorial Sloan Kettering Cancer Center, New York, NY;
Fergus Keane , Joshua David Schoenfeld , Fionnuala Crowley , Catherine Anne O'Connor , Charlie White , Carly Schwartz , Robin Brenner , Mary Larsen , Wungki Park , Anna M. Varghese , Kenneth H. Yu , Jia Li , Alice Zervoudakis , Zoe Goldberg , Joanne F. Chou , Santosha Vardhana , Marsha Reyngold , Christopher H Crane , Richard Tuli , Eileen Mary O'Reilly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03245541
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 725)
DOI
10.1200/JCO.2023.41.4_suppl.725
Abstract #
725
Poster Bd #
L12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.
First Author: Richard Tuli
Poster
2024 ASCO Annual Meeting
Phase 2 randomized study of rintatolimod following FOLFIRINOX in patients with locally advanced pancreatic adenocarcinoma.
First Author: Kelsey Klute
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).
First Author: Theodore S. Hong
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: Results of phase I study.
First Author: Eric Christenson